Immune Thrombocytopenic Purpura and Intracranial Stenting.
Sophia PathanPublished in: Journal of pharmacy practice (2024)
Patients with immune thrombocytopenic purpura (ITP) presenting with indications for dual antiplatelet therapy (DAPT) can be difficult to manage due to the precarious balance of managing the need for increased platelet counts as well as inhibition of platelet activity. This case represents a 65 year old woman with ITP who presented with a bilateral subarachnoid hemorrhage secondary to a left ophthalmic aneurysm that required placement of a pipeline embolization device (PED) necessitating DAPT. After treatment of her ITP with pulse dexamethasone for four days, she was safely discharged on one month of DAPT with aspirin and ticagrelor then switched to aspirin monotherapy without any immediate complications. During her period of DAPT, she did not receive additional medical treatment for her ITP. This case successfully presents a high-risk ITP patient requiring DAPT for a neurosurgical procedure and illustrates that these patients can be safely and successfully treated with DAPT once their ITP is stabilized.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- subarachnoid hemorrhage
- brain injury
- case report
- end stage renal disease
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- ejection fraction
- healthcare
- newly diagnosed
- coronary artery
- cerebral ischemia
- low dose
- chronic kidney disease
- blood pressure
- high dose
- type diabetes
- atrial fibrillation
- combination therapy
- randomized controlled trial
- prognostic factors
- minimally invasive
- clinical trial
- open label
- optical coherence tomography
- patient reported
- data analysis